Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (ONCY)
NASDAQ:ONCY
ONCY Stock Chart & Stats
$0.99
-$0.03(-3.70%)
At close: 4:00 PM EST
$0.99
-$0.03(-3.70%)
Day’s Range― - ―
52-Week Range$0.33 - $1.51
Previous CloseN/A
Volume216.96K
Average Volume (3M)861.50K
Market Cap
$106.15M
Enterprise Value$133.56M
Total Cash (Recent Filing)$12.35M
Total Debt (Recent Filing)$835.00K
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Mar 05, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding106,146,385
10 Day Avg. Volume655,854
30 Day Avg. Volume861,499
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)16.80
Price to Sales (P/S)0.00
P/FCF Ratio-3.69
Enterprise Value/Market Cap1.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.77
Forecast
1Y Price Target
$5.50Price Target Upside455.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe ongoing Phase 1/2 GOBLET basket study for pelareorep in gastrointestinal cancers shows promising progress, with full enrollment expected in 2026 for the pancreatic cancer arm.
Market PositionOncolytics Biotech's stock has surged over 230% since early June, attributed to internal changes like a new CEO and a streamlined strategy for pelareorep, as well as external factors such as increased activity in the oncolytic virus space.
Regulatory ApprovalThe FDA endorsed all key elements of the pivotal design, including the survival-based primary endpoint, statistical framework, and the flexibility to run a two-arm or three-arm study.
Bears Say
Clinical Development RiskRisks include clinical development risk, competitor risk, novel modality risk, reimbursement risk, pricing risk, capital market and dilution risk, and disruptions to clinical trials.
Comparison With Historical BenchmarksHistorical benchmarks with TAS-102 in 3L mCRC showed lower response rates compared to pelareorep, but overall disease control rates were similar.
Financial StabilityOncolytics Biotech has an estimated cash burn of $33 million with only C$12 million in cash and cash equivalents.
Oncolytics Biotech News
ONCY FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Oncolytics Biotech lowest stock price was $0.33 and its highest was $1.51 in the past 12 months.
What is Oncolytics Biotech’s market cap?
Oncolytics Biotech’s market cap is $106.15M.
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is Mar 05, 2026 which is in 81 days.
How were Oncolytics Biotech’s earnings last quarter?
Oncolytics Biotech released its earnings results on Nov 12, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.062 by -$0.038.
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate is -0.06.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 106,146,385 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Oncolytics Biotech reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.062. Following the earnings report the stock price went down -4.846%.
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in ONCY
Oncolytics Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.50 (455.56% Upside)
$5.50 (455.56% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.96%
12-Months-Change
Fundamentals
Return on Equity
-745.66%
Trailing 12-Months
Asset Growth
-39.74%
Trailing 12-Months
Company Description
Oncolytics Biotech
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
ONCY Stock 12 Month Forecast
Average Price Target
$5.50
▲(455.56% Upside)
Technical Analysis
Atossa Therapeutics
―
Oramed Pharm
―
Atara Biotherapeutics
―
Zentalis Pharmaceuticals
―
Prelude Therapeutics
―
Ownership Overview
1.72% Insiders
0.07% Mutual Funds
0.95% Other Institutional Investors
97.27% Public Companies and Individual Investors
Options Prices
Currently, No data available
---